These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1678 related items for PubMed ID: 16142045

  • 1. [Selective serotonin reuptake inhibitors in major depressive disorder in children and adolescents (ratio of benefits/risks)].
    Hjalmarsson L, Corcos M, Jeammet P.
    Encephale; 2005; 31(3):309-16. PubMed ID: 16142045
    [Abstract] [Full Text] [Related]

  • 2. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
    Hetrick SE, McKenzie JE, Bailey AP, Sharma V, Moller CI, Badcock PB, Cox GR, Merry SN, Meader N.
    Cochrane Database Syst Rev; 2021 May 24; 5(5):CD013674. PubMed ID: 34029378
    [Abstract] [Full Text] [Related]

  • 3. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study.
    Brent DA, Emslie GJ, Clarke GN, Asarnow J, Spirito A, Ritz L, Vitiello B, Iyengar S, Birmaher B, Ryan ND, Zelazny J, Onorato M, Kennard B, Mayes TL, Debar LL, McCracken JT, Strober M, Suddath R, Leonard H, Porta G, Keller MB.
    Am J Psychiatry; 2009 Apr 24; 166(4):418-26. PubMed ID: 19223438
    [Abstract] [Full Text] [Related]

  • 4. Newer generation antidepressants for depressive disorders in children and adolescents.
    Hetrick SE, McKenzie JE, Cox GR, Simmons MB, Merry SN.
    Cochrane Database Syst Rev; 2012 Nov 14; 11(11):CD004851. PubMed ID: 23152227
    [Abstract] [Full Text] [Related]

  • 5. A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial.
    Goodyer IM, Dubicka B, Wilkinson P, Kelvin R, Roberts C, Byford S, Breen S, Ford C, Barrett B, Leech A, Rothwell J, White L, Harrington R.
    Health Technol Assess; 2008 May 14; 12(14):iii-iv, ix-60. PubMed ID: 18462573
    [Abstract] [Full Text] [Related]

  • 6. Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine.
    Gibbons RD, Brown CH, Hur K, Davis J, Mann JJ.
    Arch Gen Psychiatry; 2012 Jun 14; 69(6):580-7. PubMed ID: 22309973
    [Abstract] [Full Text] [Related]

  • 7. [Safety of selective serotonin reuptake inhibitor antidepressants in children and adolescents].
    Bailly D.
    Presse Med; 2006 Oct 14; 35(10 Pt 2):1507-15. PubMed ID: 17028514
    [Abstract] [Full Text] [Related]

  • 8. [A place for SSRIs in the treatment of severely depressed children and adolescents].
    Roobol TH, Buitelaar JK.
    Ned Tijdschr Geneeskd; 2008 Aug 02; 152(31):1710-2. PubMed ID: 18727599
    [Abstract] [Full Text] [Related]

  • 9. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
    Brent D, Emslie G, Clarke G, Wagner KD, Asarnow JR, Keller M, Vitiello B, Ritz L, Iyengar S, Abebe K, Birmaher B, Ryan N, Kennard B, Hughes C, DeBar L, McCracken J, Strober M, Suddath R, Spirito A, Leonard H, Melhem N, Porta G, Onorato M, Zelazny J.
    JAMA; 2008 Feb 27; 299(8):901-913. PubMed ID: 18314433
    [Abstract] [Full Text] [Related]

  • 10. Comparative safety of antidepressant agents for children and adolescents regarding suicidal acts.
    Schneeweiss S, Patrick AR, Solomon DH, Dormuth CR, Miller M, Mehta J, Lee JC, Wang PS.
    Pediatrics; 2010 May 27; 125(5):876-88. PubMed ID: 20385637
    [Abstract] [Full Text] [Related]

  • 11. Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents.
    Hetrick S, Merry S, McKenzie J, Sindahl P, Proctor M.
    Cochrane Database Syst Rev; 2007 Jul 18; (3):CD004851. PubMed ID: 17636776
    [Abstract] [Full Text] [Related]

  • 12. The treatment of SSRI-resistant depression in adolescents (TORDIA): in search of the best next step.
    Brent DA.
    Depress Anxiety; 2009 Jul 18; 26(10):871-4. PubMed ID: 19798756
    [No Abstract] [Full Text] [Related]

  • 13. Switching Selective Serotonin Reuptake Inhibitors in Adolescents with Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder: Balancing Tolerability and Efficacy.
    Strawn JR, Mills JA, Croarkin PE.
    J Child Adolesc Psychopharmacol; 2019 May 18; 29(4):250-255. PubMed ID: 30810350
    [Abstract] [Full Text] [Related]

  • 14. Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents: predictors and moderators of treatment response.
    Asarnow JR, Emslie G, Clarke G, Wagner KD, Spirito A, Vitiello B, Iyengar S, Shamseddeen W, Ritz L, Birmaher B, Ryan N, Kennard B, Mayes T, DeBar L, McCracken J, Strober M, Suddath R, Leonard H, Porta G, Keller M, Brent D.
    J Am Acad Child Adolesc Psychiatry; 2009 Mar 18; 48(3):330-339. PubMed ID: 19182688
    [Abstract] [Full Text] [Related]

  • 15. Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years' data.
    Schneeweiss S, Patrick AR, Solomon DH, Mehta J, Dormuth C, Miller M, Lee JC, Wang PS.
    Arch Gen Psychiatry; 2010 May 18; 67(5):497-506. PubMed ID: 20439831
    [Abstract] [Full Text] [Related]

  • 16. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
    Lenox-Smith AJ, Jiang Q.
    Int Clin Psychopharmacol; 2008 May 18; 23(3):113-9. PubMed ID: 18408525
    [Abstract] [Full Text] [Related]

  • 17. Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder.
    Khandker RK, Kruzikas DT, McLaughlin TP.
    J Manag Care Pharm; 2008 Jun 18; 14(5):426-41. PubMed ID: 18597572
    [Abstract] [Full Text] [Related]

  • 18. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
    Olié JP, Gourion D, Montagne A, Rostin M, Poirier MF.
    Encephale; 2009 Dec 18; 35(6):595-604. PubMed ID: 20004291
    [Abstract] [Full Text] [Related]

  • 19. [Use of antidepressant drugs in schizophrenic patients with depression].
    Micallef J, Fakra E, Blin O.
    Encephale; 2006 Dec 18; 32(2 Pt 1):263-9. PubMed ID: 16910628
    [Abstract] [Full Text] [Related]

  • 20. Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression.
    Miner CM, Brown EB, Gonzales JS, Munir R.
    J Clin Psychiatry; 2002 Mar 18; 63(3):232-40. PubMed ID: 11926723
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 84.